The HONDA Patient Population- Hypertensive, Obese, Non-Compliant, Diabetic and Asthmatics- in the U.S. is a Significant Driver of Healthcare Costs Therapies Used to Treat HONDA Patients are Forecast to Be Among Highest Selling, Fastest Growing Drugs from 2012 to 2019, According to a New Report from Decision Resources
BURLINGTON, Mass., Sept. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the top 20 percent costliest patients in the United States are responsible for more than 80 percent of total healthcare costs and the top 1 percent costliest patients are responsible for more than 20 percent of all healthcare expenditures. The HONDA patient population (hypertensive, obese, non-compliant, diabetic and asthmatics) in the United States is of significant interest as a driver of healthcare costs as these patients concurrently have multiple complex comorbidities that significantly increase the risk for cardiovascular events and diabetic complications.
The report entitled Economic Burden of Chronic Disorders, a Case Study: How Far Are HONDAs Driving Healthcare Costs? finds that the U.S. HONDA population will double from 2 million prevalent cases in 2012 to more than 4 million in 2022. Additionally, therapies that are used to treat HONDA patients are forecast to be among the highest selling and fastest growing drugs from 2012 to 2019. Globally, the cardiovascular market was the highest selling therapy area in 2012, with more than $99 billion in worldwide sales, and the metabolic market will be the fastest growing therapy area over the next several years, increasing from nearly $54 billion in 2012 to more than $85 billion in 2019.
The report also finds that there is significant opportunity for the development of safe and efficacious obesity therapies that can elicit at least 10 percent weight loss, owing to the large patient population and the dearth of competing therapies. The regulatory and reimbursement environments are both improving after more than a decade during which time no new obesity drugs were approved in the U.S. Owing to the launch of new therapies, Decision Resources forecasts 51 percent annual growth in obesity drug sales in the U.S. from 2012-2016.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources